{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:40:55Z","timestamp":1792788055552,"version":"4.5.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"vor","delay-in-days":85,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the National Science Foundation of China","award":["No. 82172825"],"award-info":[{"award-number":["No. 82172825"]}]},{"name":"the National Science Foundation of China","award":["No. 82172825"],"award-info":[{"award-number":["No. 82172825"]}]},{"name":"the National Science Foundation of China","award":["No. 82172825"],"award-info":[{"award-number":["No. 82172825"]}]},{"name":"the National Science Foundation of China","award":["No. 82172825"],"award-info":[{"award-number":["No. 82172825"]}]},{"name":"the Hubei Provincial Natural Science Foundation","award":["No. 2025AFD783"],"award-info":[{"award-number":["No. 2025AFD783"]}]},{"name":"the Hubei Provincial Natural Science Foundation","award":["No. 2025AFD783"],"award-info":[{"award-number":["No. 2025AFD783"]}]},{"name":"Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology Research Fund","award":["No. 2023B37"],"award-info":[{"award-number":["No. 2023B37"]}],"id":[{"id":"https:\/\/ror.org\/00p991c53","id-type":"ROR","asserted-by":"crossref"}]},{"name":"the Wuhan Natural Science Foundation Exploration Program","award":["No. 2024040801020343"],"award-info":[{"award-number":["No. 2024040801020343"]}]},{"name":"the National Natural Science Foundation of China","award":["No. 82503681"],"award-info":[{"award-number":["No. 82503681"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"DOI":"10.1186\/s12931-026-03810-3","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T05:46:09Z","timestamp":1783575969000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Early radiotherapy delays acquired gefitinib resistance in EGFR-mutant NSCLC by suppressing c-FOS-associated survival signaling"],"prefix":"10.1186","volume":"27","author":[{"given":"Lin","family":"Peng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juejun","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yichen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyou","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinjie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"issue":"3","key":"3810_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"10","key":"3810_CR2","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1002\/cac2.12359","volume":"42","author":"P Chen","year":"2022","unstructured":"Chen P, Liu Y, Wen Y, Zhou C. Non-small cell lung cancer in China. Cancer Commun (Lond). 2022;42(10):937\u201370.","journal-title":"Cancer Commun (Lond)"},{"issue":"4","key":"3810_CR3","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/s43018-021-00195-8","volume":"2","author":"A Passaro","year":"2021","unstructured":"Passaro A, J\u00e4nne PA, Mok T, Peters S. Overcoming therapy resistance in EGFR-mutant lung cancer. Nat Cancer. 2021;2(4):377\u201391.","journal-title":"Nat Cancer"},{"key":"3810_CR4","doi-asserted-by":"publisher","first-page":"1332057","DOI":"10.3389\/fimmu.2023.1332057","volume":"14","author":"Q Chen","year":"2024","unstructured":"Chen Q, Jia G, Zhang X, Ma W. Targeting HER3 to overcome EGFR TKI resistance in NSCLC. Front Immunol. 2024;14:1332057.","journal-title":"Front Immunol"},{"key":"3810_CR5","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.lungcan.2022.05.011","volume":"170","author":"M Johnson","year":"2022","unstructured":"Johnson M, Garassino MC, Mok T, Mitsudomi T. Treatment strategies and outcomes for patients with EGFR-mutant non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors: Focus on novel therapies. Lung Cancer. 2022;170:41\u201351.","journal-title":"Lung Cancer"},{"issue":"4","key":"3810_CR6","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.3390\/ijms26041483","volume":"26","author":"L Peng","year":"2025","unstructured":"Peng L, Deng S, Li J, Zhang Y, Zhang L, Single-Cell RNA. Sequencing in Unraveling Acquired Resistance to EGFR-TKIs in Non-Small Cell Lung Cancer: New Perspectives. Int J Mol Sci. 2025;26(4):1483.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"3810_CR7","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1913662","volume":"382","author":"SS Ramalingam","year":"2020","unstructured":"Ramalingam SS, Vansteenkiste J, Planchard D, et al. Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. N Engl J Med. 2020;382(1):41\u201350.","journal-title":"N Engl J Med"},{"issue":"2","key":"3810_CR8","doi-asserted-by":"publisher","first-page":"171","DOI":"10.3892\/ijo.2021.5168","volume":"58","author":"AK Vaid","year":"2021","unstructured":"Vaid AK, Gupta A, Momi G. Overall survival in stage IV EGFR mutation\u2013positive NSCLC: Comparing first\u2013, second\u2013 and third\u2013generation EGFR\u2013TKIs (Review). Int J Oncol. 2021;58(2):171\u201384.","journal-title":"Int J Oncol"},{"issue":"21","key":"3810_CR9","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1056\/NEJMoa2306434","volume":"389","author":"D Planchard","year":"2023","unstructured":"Planchard D, J\u00e4nne PA, Cheng Y, et al. Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC. N Engl J Med. 2023;389(21):1935\u201348.","journal-title":"N Engl J Med"},{"issue":"1","key":"3810_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11523-021-00859-6","volume":"17","author":"H Tu","year":"2022","unstructured":"Tu H, Feng J, Shi M, Zhao J, Wang Y, Chang J, Wang J, Cheng Y, Zhu J, Tan E, et al. A Phase IIIb Open-Label, Single-Arm Study of Afatinib in EGFR TKI-Na\u00efve Patients with EGFRm+ NSCLC: Final Analysis, with a Focus on Patients Enrolled at Sites in China. Target Oncol. 2022;17(1):1\u201313.","journal-title":"Target Oncol"},{"issue":"6","key":"3810_CR11","doi-asserted-by":"publisher","first-page":"188967","DOI":"10.1016\/j.bbcan.2023.188967","volume":"1878","author":"S Singh","year":"2023","unstructured":"Singh S, Sadhukhan S, Sonawane A. 20 years since the approval of first EGFR-TKI, gefitinib: Insight and foresight. Biochim Biophys Acta Rev Cancer. 2023;1878(6):188967.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"1","key":"3810_CR12","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s41420-022-00966-x","volume":"8","author":"J Wang","year":"2022","unstructured":"Wang J, Liu X, Huang Y, et al. Targeting nicotinamide N-methyltransferase overcomes resistance to EGFR-TKI in non-small cell lung cancer cells. Cell Death Discov. 2022;8(1):170.","journal-title":"Cell Death Discov"},{"key":"3810_CR13","doi-asserted-by":"publisher","first-page":"101019","DOI":"10.1016\/j.drup.2023.101019","volume":"72","author":"G Wang","year":"2024","unstructured":"Wang G, Li T, Wan Y, Li Q. MYC expression and fatty acid oxidation in EGFR-TKI acquired resistance. Drug Resist Updat. 2024;72:101019.","journal-title":"Drug Resist Updat"},{"issue":"6","key":"3810_CR14","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1093\/jnci\/djac015","volume":"115","author":"XS Wang","year":"2023","unstructured":"Wang XS, Bai YF, Verma V, et al. Randomized Trial of First-Line Tyrosine Kinase Inhibitor With or Without Radiotherapy for Synchronous Oligometastatic EGFR-Mutated Non-Small Cell Lung Cancer. J Natl Cancer Inst. 2023;115(6):742\u20138.","journal-title":"J Natl Cancer Inst"},{"key":"3810_CR15","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.lungcan.2019.12.009","volume":"140","author":"Y Tang","year":"2020","unstructured":"Tang Y, Xia B, Xie R, Xu X, Zhang M, Wu K, Wang B, Ma S. Timing in combination with radiotherapy and patterns of disease progression in non-small cell lung cancer treated with EGFR-TKI. Lung Cancer. 2020;140:65\u201370.","journal-title":"Lung Cancer"},{"key":"3810_CR16","doi-asserted-by":"publisher","first-page":"1224892","DOI":"10.3389\/fimmu.2023.1224892","volume":"14","author":"D Song","year":"2023","unstructured":"Song D, Lian Y, Zhang L. The potential of activator protein 1 (AP-1) in cancer targeted therapy. Front Immunol. 2023;14:1224892.","journal-title":"Front Immunol"},{"issue":"2","key":"3810_CR17","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/s41418-023-01248-4","volume":"31","author":"GL Rampioni Vinciguerra","year":"2024","unstructured":"Rampioni Vinciguerra GL, Capece M, Scafetta G, et al. Role of Fra-2 in cancer. Cell Death Differ. 2024;31(2):136\u201349.","journal-title":"Cell Death Differ"},{"issue":"5","key":"3810_CR18","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s10142-024-01429-5","volume":"24","author":"S Wang","year":"2024","unstructured":"Wang S, Yu H, Guo P, Feng L, Li Z. C-FOS inhibition promotes pancreatic cancer cell ferroptosis by transcriptionally regulating the expression of SLC7A11. Funct Integr Genomics. 2024;24(5):163.","journal-title":"Funct Integr Genomics"},{"issue":"2","key":"3810_CR19","doi-asserted-by":"publisher","first-page":"114361","DOI":"10.1016\/j.yexcr.2024.114361","volume":"444","author":"GG Jia","year":"2025","unstructured":"Jia GG, Lu LX, Li B, et al. lncRNA-NEF regulates hepatic stellate cells proliferation, cell cycle, apoptosis and ECM synthesis through the ERK1\/2\/c-Fos axis. Exp Cell Res. 2025;444(2):114361.","journal-title":"Exp Cell Res"},{"issue":"6","key":"3810_CR20","doi-asserted-by":"publisher","first-page":"e0180558","DOI":"10.1371\/journal.pone.0180558","volume":"12","author":"Q Wang","year":"2017","unstructured":"Wang Q, Liu H, Wang Q, et al. Involvement of c-Fos in cell proliferation, migration, and invasion in osteosarcoma cells accompanied by altered expression of Wnt2 and Fzd9. PLoS ONE. 2017;12(6):e0180558.","journal-title":"PLoS ONE"},{"issue":"1","key":"3810_CR21","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/s41419-024-06451-w","volume":"15","author":"Y Gui","year":"2024","unstructured":"Gui Y, Qian X, Ding Y, et al. c-Fos regulated by TMPO\/ERK axis promotes 5-FU resistance via inducing NANOG transcription in colon cancer. Cell Death Dis. 2024;15(1):61.","journal-title":"Cell Death Dis"},{"key":"3810_CR22","doi-asserted-by":"crossref","unstructured":"Li G, Hu X, Sun L, Li X, Li J, Li T, Zhang X. C-fos upregulates P-glycoprotein, contributing to the development of multidrug resistance in hep-2 laryngeal cancer cells with VCR-induced resistance. Cell Mol Biol Lett. 2018;23(1).","DOI":"10.1186\/s11658-017-0067-8"},{"issue":"4","key":"3810_CR23","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1111\/jcmm.14086","volume":"23","author":"M Lu","year":"2019","unstructured":"Lu M, Liu B, Xiong H, Wu F, Hu C, Liu P. Trans-3,5,4\u00b4-trimethoxystilbene reduced gefitinib resistance in NSCLCs via suppressing MAPK\/Akt\/Bcl-2 pathway by upregulation of miR-345 and miR-498. J Cell Mol Med. 2019;23(4):2431\u201341.","journal-title":"J Cell Mol Med"},{"issue":"1","key":"3810_CR24","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1186\/s13046-024-03161-1","volume":"43","author":"H Zhang","year":"2024","unstructured":"Zhang H, Zhang G, Xiao M, et al. Two-polarized roles of transcription factor FOSB in lung cancer progression and prognosis: dependent on p53 status. J Exp Clin Cancer Res. 2024;43(1):237.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"3810_CR25","first-page":"243","volume":"56","author":"Y Nakano","year":"2020","unstructured":"Nakano Y, Isobe K, Kobayashi H, Kaburaki K, Isshiki T, Sakamoto S, Takai Y, Tochigi N, Mikami T, Iyoda A, et al. Clinical importance of long non-coding RNA LINC00460 expression in EGFR\u2013mutant lung adenocarcinoma. Int J Oncol. 2020;56(1):243\u201357.","journal-title":"Int J Oncol"},{"key":"3810_CR26","doi-asserted-by":"publisher","first-page":"1025872","DOI":"10.3389\/fimmu.2022.1025872","volume":"13","author":"Y Xiao","year":"2022","unstructured":"Xiao Y, Zhuang H. Effect of stereotactic radiotherapy on immune microenvironment of lung cancer. Front Immunol. 2022;13:1025872.","journal-title":"Front Immunol"},{"issue":"2","key":"3810_CR27","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1007\/s11604-024-01663-8","volume":"43","author":"K Shirai","year":"2025","unstructured":"Shirai K, Aoki S, Endo M, et al. Recent developments in the field of radiotherapy for the management of lung cancer. Jpn J Radiol. 2025;43(2):186\u201399.","journal-title":"Jpn J Radiol"},{"key":"3810_CR28","doi-asserted-by":"publisher","first-page":"109681","DOI":"10.1016\/j.radonc.2023.109681","volume":"184","author":"P Peng","year":"2023","unstructured":"Peng P, Gong J, Zhang Y, Zhou S, Li Y, Han G, Meng R, Chen Y, Yang M, Shen Q, et al. EGFR-TKIs plus stereotactic body radiation therapy (SBRT) for stage IV non-small cell lung cancer (NSCLC): A prospective, multicenter, randomized, controlled phase II study. Radiother Oncol. 2023;184:109681.","journal-title":"Radiother Oncol"},{"key":"3810_CR29","doi-asserted-by":"publisher","first-page":"e2500047","DOI":"10.1200\/PO-25-00047","volume":"9","author":"MF Chen","year":"2025","unstructured":"Chen MF, Jeng MY, Ma J, et al. Outcomes After Radiation for Oligoprogressive Disease Sites in Patients with EGFR-Mutant Lung Cancer Treated with Osimertinib. JCO Precis Oncol. 2025;9:e2500047.","journal-title":"JCO Precis Oncol"},{"issue":"6","key":"3810_CR30","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1038\/s41388-021-02122-8","volume":"41","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Zhang Y, Ai B, Gong J, Li Y, Yu S, Cai X, Zhang L. GTF2E2 is a novel biomarker for recurrence after surgery and promotes progression of esophageal squamous cell carcinoma via miR-139-5p\/GTF2E2\/FUS axis. Oncogene. 2022;41(6):782\u201396.","journal-title":"Oncogene"},{"key":"3810_CR31","first-page":"101260","volume":"53","author":"Q Zhou","year":"2024","unstructured":"Zhou Q, Zhao H, Lu S, et al. Consensus on the lung cancer management after third-generation EGFR-TKI resistance. Lancet Reg Health West Pac. 2024;53:101260.","journal-title":"Lancet Reg Health West Pac"},{"issue":"3","key":"3810_CR32","doi-asserted-by":"publisher","first-page":"104321","DOI":"10.1016\/j.drudis.2025.104321","volume":"30","author":"X Yao","year":"2025","unstructured":"Yao X, Gao C, Sun C, Chen ZS, Zhuang J. Epigenetic code underlying EGFR-TKI resistance in non-small cell lung cancer: Elucidation of mechanisms and perspectives on therapeutic strategies. Drug Discov Today. 2025;30(3):104321.","journal-title":"Drug Discov Today"},{"issue":"8","key":"3810_CR33","doi-asserted-by":"publisher","first-page":"e1364","DOI":"10.1002\/ctm2.1364","volume":"13","author":"N Osada","year":"2023","unstructured":"Osada N, Kikuchi J, Iha H, et al. c-FOS is an integral component of the IKZF1 transactivator complex and mediates lenalidomide resistance in multiple myeloma. Clin Transl Med. 2023;13(8):e1364.","journal-title":"Clin Transl Med"},{"key":"3810_CR34","doi-asserted-by":"publisher","first-page":"156604","DOI":"10.1016\/j.phymed.2025.156604","volume":"140","author":"H Yu","year":"2025","unstructured":"Yu H, Kou Q, Yuan H, et al. Alkannin triggered apoptosis and ferroptosis in gastric cancer by suppressing lipid metabolism mediated by the c-Fos\/SREBF1 axis. Phytomedicine. 2025;140:156604.","journal-title":"Phytomedicine"},{"issue":"4","key":"3810_CR35","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1038\/nm.4310","volume":"23","author":"M Kesarwani","year":"2017","unstructured":"Kesarwani M, Kincaid Z, Gomaa A, et al. Targeting c-FOS and DUSP1 abrogates intrinsic resistance to tyrosine-kinase inhibitor therapy in BCR-ABL-induced leukemia. Nat Med. 2017;23(4):472\u201382.","journal-title":"Nat Med"},{"issue":"1","key":"3810_CR36","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s13046-022-02572-2","volume":"42","author":"Y Chang","year":"2023","unstructured":"Chang Y, Huang Z, Hou F, Liu Y, Wang L, Wang Z, Sun Y, Pan Z, Tan Y, Ding L, et al. Parvimonas micra activates the Ras\/ERK\/c-Fos pathway by upregulating miR-218-5p to promote colorectal cancer progression. J Exp Clin Cancer Res. 2023;42(1):13.","journal-title":"J Exp Clin Cancer Res"},{"issue":"5","key":"3810_CR37","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1038\/s41401-021-00747-9","volume":"43","author":"C Fang","year":"2022","unstructured":"Fang C, Guo JW, Wang YJ, Li XQ, Zhang H, Cui J, Hu Y, Jing YY, Chen X, Su JC. Diterbutyl phthalate attenuates osteoarthritis in ACLT mice via suppressing ERK\/c-fos\/NFATc1 pathway, and subsequently inhibiting subchondral osteoclast fusion. Acta Pharmacol Sin. 2022;43(5):1299\u2013310.","journal-title":"Acta Pharmacol Sin"},{"key":"3810_CR38","doi-asserted-by":"crossref","unstructured":"Sun H, Li Y, Wang X, Zhou X, Rong S, Liang D, Sun G, Cao H, Sun H, Wang R et al. TRIB2 regulates the expression of miR\u201333a\u20135p through the ERK\/c\u2013fos pathway to affect the imatinib resistance of chronic myeloid leukemia cells. Int J Oncol. 2022;60(5).","DOI":"10.3892\/ijo.2022.5339"},{"issue":"1","key":"3810_CR39","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s12943-022-01547-3","volume":"21","author":"Z Pan","year":"2022","unstructured":"Pan Z, Wang K, Wang X, Jia Z, Yang Y, Duan Y, Huang L, Wu ZX, Zhang JY, Ding X. Cholesterol promotes EGFR-TKIs resistance in NSCLC by inducing EGFR\/Src\/Erk\/SP1 signaling-mediated ERR\u03b1 re-expression. Mol Cancer. 2022;21(1):77.","journal-title":"Mol Cancer"},{"key":"3810_CR40","doi-asserted-by":"publisher","first-page":"101079","DOI":"10.1016\/j.drup.2024.101079","volume":"74","author":"W Huang","year":"2024","unstructured":"Huang W, Hu X, He X, et al. TRIM29 facilitates gemcitabine resistance via MEK\/ERK pathway and is modulated by circRPS29\/miR-770-5p axis in PDAC. Drug Resist Updat. 2024;74:101079.","journal-title":"Drug Resist Updat"},{"key":"3810_CR41","first-page":"1","volume":"12","author":"D Yu","year":"2021","unstructured":"Yu D, Zhao W, Vallega KA, Sun SY. Managing Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors Through Co-Targeting MEK\/ERK Signaling. Lung Cancer (Auckl). 2021;12:1\u201310.","journal-title":"Lung Cancer (Auckl)"},{"issue":"3","key":"3810_CR42","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.jtho.2024.11.022","volume":"20","author":"A Kazi","year":"2025","unstructured":"Kazi A, Vasiyani H, Ghosh D, et al. FGTI-2734 Inhibits ERK Reactivation to Overcome Sotorasib Resistance in KRAS G12C Lung Cancer. J Thorac Oncol. 2025;20(3):331\u201344.","journal-title":"J Thorac Oncol"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12931-026-03810-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-026-03810-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-026-03810-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T23:42:05Z","timestamp":1790898125000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12931-026-03810-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,9]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3810"],"URL":"https:\/\/doi.org\/10.1186\/s12931-026-03810-3","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,9]]},"assertion":[{"value":"2 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All animal experiments were approved by the Animal Ethics Committee of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, and were conducted in accordance with institutional guidelines for the care and use of laboratory animals.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"378"}}